Merck and Mayo Clinic are partnering to use AI technology and large-scale clinical data to speed drug development in MS and ...

Continued treatment with Briumvi provided sustained clinical benefits to patients with relapsing MS, particularly when ...

UCSF is teaming up with Nektar to study NKTR-0165, an experimental antibody that activates the TNFR2 receptor, as a treatment ...

Breastfeeding for longer in infancy may be associated with lower disease severity and a later onset of MS in adulthood, a ...

A collaboration will test whether changes in a person’s voice can help detect multiple sclerosis, potentially enabling a ...

After struggling during seasons when MS took center stage, columnist Ahna Crum is enjoying the quieter days where it's only ...

MS pain is the uninvited guest you can't turn away, columnist Desiree Lama writes. Listening to your body is the key to ...

Immunic raised funds to support Phase 3 clinical trials of vidofludimus calcium for MS and transition into a commercial-stage company.

A type of immune cell targeting the Epstein-Barr virus may play a key role in driving multiple sclerosis (MS), a study found.

Tolebrutinib failed to lower disability progression risk in primary progressive MS in a Phase 3 trial, with data shown at ...

TG Therapeutics is gearing up for a new clinical trial, dubbed ULTIMATE, to test Briumvi in children and adolescents with ...

In people with early MS, diet may correlate with biological aging and the development of disease-related disability, study ...